重症患者应激性溃疡预防中停用泮托拉唑:一项先导随机临床试验与荟萃分析
该先导试验在加拿大、沙特阿拉伯和澳大利亚的10个ICU纳入91例预期机械通气≥48小时的成人ICU患者,随机接受每日静脉泮托拉唑40 mg或安慰剂,排除近期消化道出血、使用双联抗血小板药物、需质子泵抑制剂治疗或已每日接受超过一剂抑酸治疗者。可行性目标均达到:招募率2.6例/月,同意率77.8%,方案依从性97.7%。泮托拉唑组与安慰剂组上消化道出血发生率分别为6.1%和4.8%(p=1.0),呼吸机相关性肺炎分别为20.4%和14.3%(p=0.58),艰难梭菌检出分别为4.1%和2.4%(p=1.0)。对5项试验(604例)的荟萃分析显示,质子泵抑制剂与安慰剂相比,上消化道出血、感染或死亡风险无统计学显著差异。
要点
- 在预期机械通气≥48小时的成人ICU患者中,泮托拉唑组上消化道出血6.1%,安慰剂组4.8%(p=1.0),无统计学显著差异。
- 泮托拉唑组呼吸机相关性肺炎20.4%,安慰剂组14.3%(p=0.58);艰难梭菌检出分别为4.1%和2.4%(p=1.0),差异均无统计学意义。
- 荟萃分析纳入5项试验共604例患者,质子泵抑制剂与安慰剂相比,上消化道出血、感染或死亡风险无统计学显著差异。
- 该先导试验达到全部可行性目标:招募率2.6例/月、同意率77.8%、方案依从性97.7%。
- 作者认为结果支持开展更大规模试验以评估停用应激性溃疡预防的安全性,但结果不精确。
适用人群与场景
- 10个ICU中预期机械通气持续≥48小时的成人ICU患者。
- 排除有急性或近期消化道出血、使用双联抗血小板药物、患有需要质子泵抑制剂治疗的疾病、或已每日接受超过一剂抑酸治疗的患者。
处置流程与药物剂量
- 每日静脉给予泮托拉唑40 mg或安慰剂,患者、家属、临床医生和研究 staff 均设盲。
研究设计与关键结果
- 多中心先导随机临床试验,纳入加拿大、沙特阿拉伯和澳大利亚10个中心的91例患者(泮托拉唑组49例,安慰剂组42例)。
- 可行性目标:招募率2.6例/月,同意率77.8%,方案依从性97.7%。
- 上消化道出血:泮托拉唑组6.1% vs 安慰剂组4.8%(p=1.0)。
- 呼吸机相关性肺炎:泮托拉唑组20.4% vs 安慰剂组14.3%(p=0.58)。
- 艰难梭菌检出:泮托拉唑组4.1% vs 安慰剂组2.4%(p=1.0)。
- 荟萃分析5项试验共604例患者,质子泵抑制剂与安慰剂相比,上消化道出血、感染或死亡风险无统计学显著差异。
证据类型、等级与局限
- 证据类型:先导随机临床试验及系统评价与荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为结果支持开展更大规模试验以评估停用应激性溃疡预防的安全性。
- 作者指出,尽管结果不精确,上消化道出血风险未出现令人担忧的增加;质子泵抑制剂对呼吸机相关性肺炎和艰难梭菌的影响仍不明确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: A decreased frequency of upper gastrointestinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and ventilator-associated pneumonia have raised concerns recently. The Reevaluating the Inhibition of Stress Erosions Pilot Trial determined the feasibility of undertaking a larger trial investigating the efficacy and safety of withholding proton pump inhibitors in critically ill patients.
METHODS: In 10 ICUs, we randomized adult ICU patients anticipated to be mechanically ventilated for greater than or equal to 48 hours to receive 40 mg of IV pantoprazole daily or placebo. We excluded patients who had acute or recent gastrointestinal bleed, used dual antiplatelet agents, had a medical condition requiring proton pump inhibitor treatment, or had already received more than one dose of acid suppression daily. Patients, families, clinicians, and research staff were blinded. We conducted a systematic review and meta-analysis of similar trials.
MAIN RESULTS: Ninety-one patients (49 pantoprazole and 42 placebo) from 10 centers in Canada, Saudi Arabia, and Australia were enrolled. All feasibility goals were met: 1) recruitment rate was 2.6 patients per month; 2) consent rate was 77.8%; and 3) protocol adherence was 97.7%. Upper gastrointestinal bleeding developed in 6.1% of patients in the pantoprazole group and 4.8% in the placebo group (p = 1.0). Ventilator-associated pneumonia developed in 20.4% of patients in the pantoprazole group and 14.3% in the placebo group (p = 0.58). C. difficile was identified in 4.1% pantoprazole patients and in 2.4% placebo patients (p = 1.0). We meta-analyzed five trials (604 patients) of proton pump inhibitors versus placebo; there was no statistically significant difference in the risk of upper gastrointestinal bleeding, infections, or mortality.
CONCLUSIONS: Our results support the feasibility of a larger trial to evaluate the safety of withholding stress ulcer prophylaxis. Although the results are imprecise, there was no alarming increase in the risk of upper gastrointestinal bleeding; the effect of proton pump inhibitors on ventilator-associated pneumonia and C. difficile remain unclear.
参考来源
- Alhazzani W, Guyatt G, Alshahrani M, et al. Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis. Crit Care Med. 2017. PMID: 28459708. doi:10.1097/CCM.0000000000002461
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。